Logo

Amgen's Repatha (evolocumab) Receives NMPA (CFDA) Approval for Reduction of Cardiovascular Risks in China

Share this

Amgen's Repatha (evolocumab) Receives NMPA (CFDA) Approval for Reduction of Cardiovascular Risks in China

Shots:

  • The expanded indication approval is based on the results of P-III FOURIER study assessing Repatha (140mg q2w- 420 mg/month) vs PBO + statin therapy in patients with cardiovascular events
  • The study resulted in a reduction in risk of heart attack by 27%- risk of stroke by 21%- the risk of coronary revascularization by 22% and an overall reduction in cardiovascular events with safe and efficate results
  • Repatha (evolocumab) is a mAb that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9) and received NMPA approval on 31 Jul- 2018 for homozygous familial hypercholesterolemia (HoFH) in adults
Click Here   Ref: Press Reader | Image: Pic Sunday  

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions